What Is Semax?
Semax is a synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4–10), developed in Russia in the 1980s by the Institute of Molecular Genetics of the Russian Academy of Sciences. Unlike its parent peptide ACTH, semax lacks adrenocortical stimulating activity, and its research interest centers on neuroprotective, nootropic, and neurotrophic effects observed in preclinical and clinical studies.
The amidate form (semax amidate) is a modified variant with enhanced stability and resistance to enzymatic degradation compared to unmodified semax. N-Acetyl Semax Amidate (NA-Semax Amidate) represents a further modification — acetylation of the N-terminus — that research suggests provides greater potency and duration of action in neurological models.
Semax Mechanism of Action
Semax acts through several interconnected neurobiological pathways:
- BDNF upregulation: Research in rodent and cell culture models demonstrates semax significantly increases brain-derived neurotrophic factor (BDNF) expression — a key mediator of neuronal survival, synaptic plasticity, and neurogenesis
- VEGF modulation: Preclinical data shows semax promotes vascular endothelial growth factor expression, supporting cerebrovascular research applications
- Dopaminergic and serotonergic effects: Animal studies have documented semax-induced changes in dopamine and serotonin metabolism in limbic and cortical regions
- Anti-inflammatory neuroprotection: Semax has been shown to reduce neuroinflammatory markers in ischemia and traumatic brain injury models in rodents
Semax Research Data
Semax has a broader clinical research base than most neuropeptides, with published data from Russian institutions across multiple neurological conditions:
- Ischemic stroke: Multiple Russian clinical studies reported improved neurological recovery scores and reduced infarct-related complications in patients treated with semax within 24 hours of ischemic stroke onset
- Optic nerve disease: A published clinical trial demonstrated semax improved visual acuity and visual field parameters in patients with optic nerve atrophy compared to controls
- Cognitive function: Preclinical studies consistently demonstrate semax enhances learning and memory consolidation in rodent maze models, associated with BDNF upregulation in the hippocampus
- ADHD research: Preliminary Russian clinical data has been published on semax in attention-deficit models, though this remains a limited research area requiring further investigation
Semax Amidate Dosage Reference
| Research Context | Dose from Published Studies | Route |
|---|---|---|
| Ischemic stroke (clinical) | 12–18 mcg/kg/day | Intranasal |
| Optic nerve studies (clinical) | 200–400 mcg/day | Intranasal |
| Cognitive/rodent models | 50–200 mcg/kg | IP or intranasal |
| NA-Semax Amidate (preclinical) | Approx. 5–10x lower than unmodified semax | Intranasal |
Published literature data provided for research reference only. Not dosing guidance for human use.
Side Effects from Research Data
Semax has a well-documented tolerability profile in published Russian clinical studies:
- Generally well-tolerated across published clinical applications
- Occasional nasal irritation with intranasal administration
- Mild anxiety or irritability reported in some subjects at higher doses in observational data
- No significant systemic toxicity signals in published clinical research
Semax vs. Selank — Neuropeptide Research Comparison
| Parameter | Semax Amidate | Selank |
|---|---|---|
| Peptide origin | ACTH 4-10 fragment | Tuftsin analogue |
| Primary research focus | Neuroprotection, BDNF upregulation | Anxiolytic, immune modulation |
| Dopaminergic effects | Stimulating | Calming/stabilizing |
| Typical research route | Intranasal | Intranasal |
| Clinical data availability | Moderate (Russian literature) | Limited |
Where to Buy Semax Amidate for Research
Semax peptide stability is highly sensitive to formulation and storage conditions. Key supplier criteria for researchers:
- HPLC purity ≥99% with batch documentation
- MS/MS sequence verification to confirm peptide identity
- Proper lyophilized or stabilized liquid formulation
- Third-party independent COA
- Cold chain handling and storage protocols
Core Power Peptides supplies Semax 10mg and N-Acetyl Selank Amidate Spray at ≥99% purity, HPLC and MS/MS verified, with third-party COA on request.
Research Disclaimer: All information on this page is for educational and scientific reference purposes only. Semax and its analogues are not approved for therapeutic use in most jurisdictions. This product is sold strictly for in vitro research and laboratory use only. Not for human consumption. Not medical advice.